165 related articles for article (PubMed ID: 37005667)
1. Prognostic marker C3AR1 is associated with ovarian cancer cell proliferation and immunosuppression in the tumor microenvironment.
Huang J; Zhou L; Deng K
J Ovarian Res; 2023 Apr; 16(1):64. PubMed ID: 37005667
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor 2 mRNA-binding protein 2 is a therapeutic target in ovarian cancer.
Yuan J; Li X; Wang F; Liu H; Guan W; Xu G
Exp Biol Med (Maywood); 2023 Dec; 248(23):2198-2209. PubMed ID: 38084732
[TBL] [Abstract][Full Text] [Related]
3. ALKBH5 modulates macrophages polarization in tumor microenvironment of ovarian cancer.
An Y; Duan H
J Ovarian Res; 2024 Apr; 17(1):84. PubMed ID: 38637813
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of prognosis-related genes in the tumor microenvironment of esophageal squamous cell carcinoma.
Qu J; Zhao Q; Yang L; Ping Y; Zhang K; Lei Q; Liu F; Zhang Y
Int Immunopharmacol; 2021 Jul; 96():107616. PubMed ID: 34162127
[TBL] [Abstract][Full Text] [Related]
5. High Expression of the Component 3a Receptor 1 (C3AR1) Gene in Stomach Adenocarcinomas Infers a Poor Prognosis and High Immune-Infiltration Levels.
Yang H; Li L; Liu X; Zhao Y
Med Sci Monit; 2021 Feb; 27():e927977. PubMed ID: 33539329
[TBL] [Abstract][Full Text] [Related]
6. PROS1 shapes the immune-suppressive tumor microenvironment and predicts poor prognosis in glioma.
Wang J; Wu N; Feng X; Liang Y; Huang M; Li W; Hou L; Yin C
Front Immunol; 2022; 13():1052692. PubMed ID: 36685506
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer.
Gao L; Ying F; Cai J; Peng M; Xiao M; Sun S; Zeng Y; Xiong Z; Cai L; Gao R; Wang Z
J Ovarian Res; 2023 Jan; 16(1):27. PubMed ID: 36707884
[TBL] [Abstract][Full Text] [Related]
8. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
Xu F; Liu T; Zhou Z; Zou C; Xu S
Front Immunol; 2021; 12():749369. PubMed ID: 34745121
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
11. SETDB1 promotes progression through upregulation of SF3B4 expression and regulates the immunity in ovarian cancer.
Yang H; Sui L; Cai C; Chu H; Diao Y
J Ovarian Res; 2024 Feb; 17(1):34. PubMed ID: 38317200
[TBL] [Abstract][Full Text] [Related]
12. RNA demethylase ALKBH5 suppresses tumorigenesis via inhibiting proliferation and invasion and promoting CD8
Ge J; Liu SL; Zheng JX; Shi Y; Shao Y; Duan YJ; Huang R; Yang LJ; Yang T
Transl Oncol; 2023 Aug; 34():101683. PubMed ID: 37224767
[TBL] [Abstract][Full Text] [Related]
13. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
[TBL] [Abstract][Full Text] [Related]
14. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
15. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
PeerJ; 2022; 10():e14432. PubMed ID: 36518297
[TBL] [Abstract][Full Text] [Related]
16. Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer.
Yu L; Ding Y; Wan T; Deng T; Huang H; Liu J
Front Immunol; 2021; 12():768115. PubMed ID: 34966389
[TBL] [Abstract][Full Text] [Related]
17. C3AR1 mRNA as a Potential Therapeutic Target Associates With Clinical Outcomes and Tumor Microenvironment in Osteosarcoma.
Zou T; Liu W; Wang Z; Chen J; Lu S; Huang K; Li W
Front Med (Lausanne); 2021; 8():642615. PubMed ID: 33748161
[No Abstract] [Full Text] [Related]
18. CCL19: a novel prognostic chemokine modulates the tumor immune microenvironment and outcomes of cancers.
Gu Q; Zhou S; Chen C; Wang Z; Xu W; Zhang J; Wei S; Yang J; Chen H
Aging (Albany NY); 2023 Nov; 15(21):12369-12387. PubMed ID: 37944262
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Analysis of Prognostic Value of MEX3A and Its Relationship with Immune Infiltrates in Ovarian Cancer.
Zhang P; Su T; Zhang S
J Immunol Res; 2021; 2021():5574176. PubMed ID: 34189143
[TBL] [Abstract][Full Text] [Related]
20.
Chen L; Lin J; Lan B; Xiong J; Wen Y; Chen Y; Chen CB
Comput Math Methods Med; 2022; 2022():5851755. PubMed ID: 36510584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
